← Search another drug
PatientPulse · by PatientPartner
Skyrizi risankizumab
High confidence
~53 public patient conversations and reviews referenced (blogs, forums, review sites, brand testimonials)
Executive intelligence
The signal that moves starts & adherence
58%Positive sentiment in discussion
76,587FDA adverse-event reports
65%Flagged serious
57%Reports name female patients
The single sharpest commercial signal: Skyrizi patients who clear or reach remission become fierce brand advocates, but the insurance-approval gauntlet and novel OBI device are the top dropout moments before efficacy can be proven.
- Skyrizi delivers life-altering efficacy for refractory psoriasis and Crohn's patients, with multiple patients describing complete or near-complete clearance after decades of failed biologics.
- The infusion-loading phase and on-body injector (OBI) device are the two highest-friction onboarding moments, creating anxiety and scheduling burden that the Nurse Ambassador program partially but not fully resolves.
- Cost and insurance access dominate forum conversations, with Medicare patients facing estimated annual out-of-pocket exposure that shocks even insurance professionals, and commercially insured patients relying heavily on the Skyrizi Complete savings card.
- Unexplained weight changes and off-label curiosity about combining Skyrizi with GLP-1 agents are rising emerging signals that physicians are currently underprepared to address, creating patient trust gaps.